Acta Neuropharmacologica››2015,Vol. 5››Issue (4): 43-54.

Previous ArticlesNext Articles

Research Progress of Estrogen Signal Pathway in Alzheimer’s Disease

LIU Yang, SHEN Li-Xia

  1. Department of Pharmacy, Hebei North University, Zhangjiakou, 075000, China
  • Online:2015-08-26Published:2016-03-03
  • Contact:沈丽霞,女,教授,博士,研究生导师;研究方向:神经药理学;Tel:+86-0313-4029305,E-mail: shenlixiacn@163.com
  • About author:刘杨,女,硕士研究生;研究方向:神经药理学;Tel: +86-0313-4029305,E-mail: LiuYangPharmacy@163.com
  • Supported by:

    河北省自然科学基金资助项目(No.H2012405016),河北省高等学校科学技术研究项目(No.ZD2015131)

Abstract:Alzheimer's disease(AD) is a common neurodegenerative diseases,and main symptomsare progressive cognitive dysfunction and memory deteriora -tion.Numerous clinical and epidemiological studies show that there is a gender difference in the incidence of AD,women are more likely to develop AD post-menopause,indicating the lack of estrogen is a risk factor of AD.Recent research has proposed estrogen can directly reduce the accumulation of senile plaqueand neurofibrillarytangles, the two significant pathological characteristics of AD. Studies have showed that estrogen may has neuroprotective effects,while clinical trials of women post-menopausal show no obvious effects of estrogen on AD.The discrepancies may related to the selectivity of estrogen receptors.This review will make a brief summary on AD related estrogen and estrogen receptors such as ER alpha or ER beta subtype,further discussing selective ligands of estrogen receptors provided a safe and effective treatment to AD.

Key words:estrogen,estrogen receptor,Alzheimer's disease

Baidu
map